Cerevance

Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, the company generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.

Cerevance headquartered in United States, North America, operates in the Biotechnology, Life Science, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $18.2B in funding across 96 round(s). With a team of 51-100 employees, Cerevance is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Cerevance, raised $21.5M. Discover more about their projects, partnerships, and impact on our platform.